Supreme Court slams 'extortionate' cancer drug markup in Indian hospitals

The Supreme Court of India has taken a critical stance against what it termed exploitative pricing practices in the distribution of cancer treatment drugs, particularly through hospital-affiliated pharmacies. The court's intervention highlights concerns about patients being charged prices far exceeding the maximum retail price set by manufacturers, effectively pricing life-saving medications beyond the reach of many Indians battling the disease. The judgment underscores the growing problem of price manipulation at the point of patient care, where hospitals leverage their position to mark up essential medications significantly. The court's strong language—comparing the practice to robbery—reflects mounting judicial concern over profiteering in the healthcare sector at the expense of vulnerable cancer patients. The case raises broader questions about regulatory oversight of drug pricing and the need for stronger mechanisms to ensure affordable access to oncology treatments across India's healthcare system.